Metagenics acquires liquid multi-strain probiotic brand Symprove
Key takeaways
- Metagenics is expanding its gut health portfolio by acquiring Symprove, a UK-based brand known for its clinically proven liquid probiotic delivery system.
- The acquisition is supported by a strategic debt recapitalization aimed at fueling further global mergers and acquisitions for US-based Metagenics.
- Metagenics plans to leverage its international network of healthcare practitioners to scale Symprove’s technology and reach a wider global consumer market.
(All image credits: Symprove).Supplement brand Metagenics has acquired the UK-based probiotic brand Symprove from Bd-capital. Symprove offers a clinically proven, water-based formula that addresses digestive illnesses and discomfort through boosting gut microbiome health.
Coinciding with this deal, US-based Metagenics and its sponsor, Gryphon Investors, completed a strategic debt recapitalization to provide Metagenics with sufficient capital to continue investing in growth opportunities in mergers and acquisitions.
Symprove will continue to be led by its CEO, Will Bowler. Terms of the transaction were not disclosed.
“After substantial growth during our partnership with Bd-capital, becoming part of Metagenics is a great next step for Symprove as we look to scale and reach a wider market,” comments Bowler.
Liquid multi-strain product
Symprove’s liquid format contains live, active multi-strain bacteria, supported by its patented delivery system, allowing the bacteria to “arrive, survive, and thrive” in the gut. The brand states its daily-use product is growing rapidly, fueled by increasing consumer awareness and recommendations from global doctors and nutritionists.
“Symprove’s differentiated product is highly strategic for Metagenics’s portfolio of practitioner-recommended supplements,” says Ryan Fagan, deal partner in Gryphon’s Consumer Group.
“Through its global network of partnerships with healthcare practitioners, Metagenics will be able to grow patient engagement and improve patient results with Symprove’s technology in markets around the world.”
“This acquisition is a significant inflection point for our partnership with Metagenics, and we are eager to pursue similar strategic acquisition opportunities.”
Symprove’s liquid format contains live, active multi-strain bacteria, supported by its patented delivery system, allowing the bacteria to “arrive, survive, and thrive” in the gut.Meanwhile, Patrick Sly, Metagenics CEO, comments: “[Symprove’s] science-based, unique probiotic formulation centers on the gut microbiome — a core area for Metagenics — and is a great fit for our family of supplements.”
“We look forward to working with Bowler and his team to further develop products that we believe will support the health and wellness of millions of consumers globally.”
Probiotic developments
In the latest headlines on the burgeoning gut health field, AceBiome and Bactolife’s entered a Joint Development Agreement to explore novel ingredients and expand their presence in global health markets. The companies will conduct studies together on gut health while exploring broader dimensions of overall health.
A recent clinical trial found that daily supplementation with Verb Biotics’ Lactiplantibacillus plantarum probiotic improved sleep quality, reduced stress, and increased urinary gamma-aminobutyric acid (GABA) levels. People Science executed the decentralized trial through its proprietary platform, Chloe.
Probiotic supplementation was also found to help restore the gut microbiomes of infants who have been exclusively breastfed, according to separate research. Recent trends reveal these babies in high-resource regions are experiencing a decline in beneficial gut bacteria, specifically Bifidobacterium infantis.
